Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the acceptance of their abstract for presentation at the ESMO Congress 2025 in Berlin. The presentation will showcase updated clinical data from their Phase 1/2 study of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate.
The study (NCT06265727) is evaluating CRB-701 in patients with advanced solid tumors expressing Nectin-4. Part A evaluated four doses (1.8-4.5 mg/kg Q3W), with ongoing dose optimization in Part B at 2.7 and 3.6 mg/kg cohorts in HNSCC, cervical, and mUC tumors. The company expects to identify a recommended Phase 2 dose in Q4 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) ha annunciato l'accettazione del loro abstract per la presentazione al Congresso ESMO 2025 a Berlino. La presentazione mostrerà dati clinici aggiornati dal loro studio di Fase 1/2 su CRB-701, un coniugato anticorpo-farmaco di nuova generazione che prende di mira Nectin-4.
Lo studio (NCT06265727) valuta CRB-701 in pazienti con tumori solidi avanzati che esprimono Nectin-4. La Parte A ha valutato quattro dosi (1,8-4,5 mg/kg ogni 3 settimane), con un'ottimizzazione della dose in corso nella Parte B nei gruppi da 2,7 e 3,6 mg/kg in tumori HNSCC, cervicali e mUC. L'azienda prevede di identificare una dose raccomandata per la Fase 2 nel Q4 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) anunció la aceptación de su resumen para presentación en el Congreso ESMO 2025 en Berlín. La presentación mostrará datos clínicos actualizados de su estudio de Fase 1/2 de CRB-701, un conjugado anticuerpo-fármaco de próxima generación dirigido a Nectin-4.
El estudio (NCT06265727) está evaluando CRB-701 en pacientes con tumores sólidos avanzados que expresan Nectin-4. La Parte A evaluó cuatro dosis (1.8-4.5 mg/kg cada 3 semanas), con optimización de dosis en curso en la Parte B en cohortes de 2.7 y 3.6 mg/kg en tumores HNSCC, cervicales y mUC. La compañía espera identificar una dosis recomendada para la Fase 2 en el Q4 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP)는 베를린에서 열리는 ESMO 2025 학회에서 초록이 채택되었음을 발표했습니다. 이번 발표에서는 차세대 Nectin-4 표적 항체-약물 접합체인 CRB-701의 1/2상 임상 데이터 업데이트를 선보일 예정입니다.
해당 연구(NCT06265727)는 Nectin-4를 발현하는 진행성 고형암 환자들을 대상으로 CRB-701을 평가하고 있습니다. 1부에서는 4가지 용량(1.8-4.5 mg/kg 3주 간격)을 평가했으며, 2부에서는 HNSCC, 자궁경부암, mUC 종양 환자군에서 2.7 및 3.6 mg/kg 용량 최적화를 진행 중입니다. 회사는 2025년 4분기에 2상 권장 용량을 결정할 것으로 기대하고 있습니다.
Corbus Pharmaceuticals (NASDAQ : CRBP) a annoncé l'acceptation de leur résumé pour une présentation au Congrès ESMO 2025 à Berlin. La présentation mettra en avant des données cliniques actualisées issues de leur étude de phase 1/2 portant sur CRB-701, un conjugué anticorps-médicament de nouvelle génération ciblant Nectin-4.
L'étude (NCT06265727) évalue CRB-701 chez des patients atteints de tumeurs solides avancées exprimant Nectin-4. La partie A a testé quatre doses (1,8-4,5 mg/kg toutes les 3 semaines), avec une optimisation des doses en cours dans la partie B sur les cohortes à 2,7 et 3,6 mg/kg dans les tumeurs HNSCC, cervicales et mUC. La société prévoit d'identifier une dose recommandée pour la phase 2 au 4e trimestre 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) gab die Annahme ihres Abstracts für die Präsentation auf dem ESMO-Kongress 2025 in Berlin bekannt. Die Präsentation wird aktualisierte klinische Daten aus ihrer Phase-1/2-Studie zu CRB-701, einem neuartigen Antikörper-Wirkstoff-Konjugat, das Nectin-4 gezielt angreift, vorstellen.
Die Studie (NCT06265727) bewertet CRB-701 bei Patienten mit fortgeschrittenen soliden Tumoren, die Nectin-4 exprimieren. Teil A untersuchte vier Dosierungen (1,8-4,5 mg/kg alle 3 Wochen), mit laufender Dosisoptimierung in Teil B bei den Kohorten mit 2,7 und 3,6 mg/kg in HNSCC-, Zervix- und mUC-Tumoren. Das Unternehmen erwartet, eine empfohlene Phase-2-Dosis im 4. Quartal 2025 zu identifizieren.
- None.
- None.
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the United States and Europe of CRB-701 (SYS6002) has been accepted for presentation as a poster at the European Society for Medical Oncology (ESMO) Congress 2025, to be held October 17-21, 2025 in Berlin, Germany.
The abstract, a Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours by Perez et al, will be presented as a poster (# 967P) on Sunday, October 19 from 12:00-12:45 CEST.
The three-part Phase 1/2 study (NCT06265727) is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg Q3W) and is being followed by Part B (dose optimization) and Part C (dose expansion). Dose optimization is on-going with dosing at 2.7 mg/kg and 3.6 mg/kg cohorts in HNSCC, cervical and mUC tumors. The Company expects to complete dose optimization and identify a recommended Phase 2 dose in the fourth quarter of 2025.
About CRB-701
CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
FAQ
When will Corbus Pharmaceuticals (CRBP) present their CRB-701 clinical data at ESMO 2025?
What is CRB-701 and what is it being studied for?
What doses of CRB-701 are being evaluated in the CRBP Phase 1/2 trial?
When does Corbus (CRBP) expect to determine the recommended Phase 2 dose for CRB-701?
Which types of cancers are being studied in the CRB-701 trial?
